Moderna and the University of Oxford Receive UK Authorization to Begin Phase 1/2 Study of Investigational mRNA Cancer Vaccine for People with Lynch Syndrome

Rhea-AI Summary

Moderna (NASDAQ:MRNA) and the University of Oxford received UK MHRA authorization to begin a Phase 1/2 INTERCEPT-Lynch study of mRNA-4194, an investigational mRNA cancer vaccine for people with Lynch syndrome.

The trial will assess safety, immune response and dosing, within a broader 10-year UK strategic mRNA partnership.

Positive

• UK MHRA authorization for Phase 1/2 study of mRNA-4194 in Lynch syndrome
• mRNA-4194 is Moderna's first investigational cancer prevention program
• Phase 1/2 trial funded by Moderna and sponsored by the University of Oxford
• First patient dosing anticipated in the UK in summer 2026
• Second-phase expansion across multiple UK centers expected to begin in 2027
• Part of 10-year UK partnership including MITC opening and over 20 UK trials

Negative

• None.

News Market Reaction – MRNA

+0.27%

+0.27% Session close to close

In the Jun 9 session, MRNA gained 0.27%, reflecting a mild positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement highlights MHRA authorization for a Phase 1/2 study of Moderna’s investigational m...

Analysis

This announcement highlights MHRA authorization for a Phase 1/2 study of Moderna’s investigational mRNA-4194 cancer vaccine for people with Lynch syndrome, part of a broader 10-year UK partnership. It underscores a strategic push into cancer prevention, beyond infectious-disease vaccines. The trial will start in the UK, expand in 2027, and assess safety, immune response, and dosing. Investors may watch enrollment progress, future efficacy signals, and how this program complements other oncology and vaccine candidates across Moderna’s mRNA platform.

Key Figures

Lifetime cancer risk: up to 80% Prevalence: 1 in 300 people Strategic partnership length: 10 years +5 more

8 metrics

Lifetime cancer risk up to 80% Cancer risk for people with Lynch syndrome

Prevalence 1 in 300 people Frequency of Lynch syndrome in the general population

Strategic partnership length 10 years Duration of Moderna–UK Government mRNA partnership established in 2022

Clinical trials delivered more than 20 Number of UK-based clinical trials under the Moderna Strategic Partnership

Trial centers 135 centers UK sites participating in Moderna partnership clinical trials

Participants enrolled more than 14,500 Cumulative enrollment in UK partnership trials to date

Second phase start 2027 Planned start year for expanded Phase 2 INTERCEPT-Lynch enrollment

MITC opening September 2025 Opening date of Moderna Innovation and Technology Centre in Harwell, UK

Previous Clinical trial Reports

5 past events · Latest: May 06 (Positive)

Same Type Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
May 06	Flu Phase 3 data	Positive	-0.5%	Phase 3 mRNA-1010 data with detailed rVE and ongoing global reviews.
Apr 21	Pandemic flu Phase 3	Positive	+0.9%	Initiation of Phase 3 H5 mRNA-1018 trial with CEPI funding support.
Apr 17	Cancer therapy data	Positive	-1.8%	Strong Phase 1/2 mRNA-4359 melanoma data and FDA Fast Track status.
Jan 20	Melanoma 5-year data	Positive	+2.8%	Five-year KEYNOTE-942 melanoma data showing reduced recurrence or death.
Dec 18	CEPI Phase 3 funding	Positive	+1.4%	CEPI committing funding for pivotal Phase 3 H5 influenza vaccine trial.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Clinical trial headlines for MRNA have often been positive, but price reactions were mixed, with both gains and declines following strong data updates.

Recent Company History

Over the last six months, Moderna has repeatedly highlighted progress in its mRNA pipeline. Clinical-trial news included Phase 3 data for flu candidate mRNA-1010 on May 6, 2026, initiation of a Phase 3 H5 pandemic flu study with CEPI funding, and multiple oncology updates such as high-response Phase 1/2 data for mRNA-4359 and five-year melanoma data for intismeran autogene with KEYTRUDA. These events show a shift from pandemic-only focus toward diversified vaccines and cancer immunotherapies, providing context for today’s Lynch syndrome prevention trial.

Key Terms

lynch syndrome, mRNA, phase 1/2, cancer vaccine, +4 more

8 terms

lynch syndrome medical

"Lynch syndrome is an inherited condition affecting 1 in 300 people..."

An inherited genetic condition that greatly raises a person’s lifetime risk of certain cancers, most often colorectal and endometrial cancer. It occurs when a cell’s “spell-check” for DNA errors is faulty, making tumors more likely and often changing how cancers are screened and treated; that matters to investors because it drives demand for genetic testing, targeted therapies, screening services and can affect healthcare costs and biotech company prospects.

mRNA medical

"a Phase 1/2 study of mRNA-4194, Moderna's investigational mRNA-based cancer vaccine..."

mRNA, short for messenger ribonucleic acid, is a biological molecule that carries instructions from a cell’s genetic blueprint to make specific proteins — like a recipe or software code that tells a kitchen or computer what to produce. Investors care because mRNA is used as a flexible drug and vaccine platform that can be developed and scaled faster than many traditional medicines; its commercial prospects, manufacturing needs, regulatory approval path, and patent position can strongly affect a company’s value.

phase 1/2 medical

"The Phase 1/2 study, funded by Moderna, sponsored by the University of Oxford..."

Phase 1/2 is a combined early-stage clinical trial that first tests a new drug or treatment for safety and the right dose, then quickly expands to check if it shows any signs of working in patients. For investors, results from a Phase 1/2 study offer an early read on both risk and potential reward—like a prototype test that both confirms a product won’t harm users and suggests whether it could sell—helping guide valuation and development decisions.

cancer vaccine medical

"investigational mRNA-based cancer vaccine for Lynch Syndrome..."

A cancer vaccine is a medicine that trains the immune system to recognize and attack cancer cells or to prevent cancers caused by infectious agents, similar to how a wanted poster helps police spot a suspect. It matters to investors because these vaccines can reshape treatment options and create large markets if proven safe and effective, but they also carry high development costs, long clinical testing periods and binary regulatory risks that make outcomes and valuations volatile.

medicines and healthcare products regulatory agency regulatory

"has received Medicines and Healthcare products Regulatory Agency (MHRA) authorization in the UK."

A medicines and healthcare products regulatory agency is a government body that assesses, licenses and monitors the safety, effectiveness and quality of medicines, vaccines and medical devices before and after they reach the market. For investors, its decisions act like a building inspector’s approval — they determine whether a product can be sold, the timing and scope of market access, and can therefore quickly affect a company’s revenue prospects, costs and valuation.

mhra regulatory

"This MHRA authorization marks an important milestone as we explore approaches..."

The MHRA is the United Kingdom’s government agency that checks and approves medicines, medical devices and vaccines before they can be sold, and monitors their safety once on the market. For investors, MHRA decisions act like a building inspector’s sign-off or a traffic controller’s clearance—approval clears the way for sales and revenue, while safety warnings, recalls or delays can slow launches, raise costs or hurt a product’s commercial prospects.

pre-cancer medical

"to recognize early cancer changes, or what we call 'pre-cancer,' we hope to reduce cancer risk..."

Pre-cancer describes abnormal cells or tissue changes that are not yet invasive cancer but have a higher chance of becoming cancer over time, like small cracks that could grow into structural damage if untreated. Investors care because detecting or treating pre-cancer can create large markets for screening tests, preventive drugs, and procedures, influence clinical trial design and regulatory pathways, and affect long-term revenue and reimbursement prospects for healthcare companies.

pandemic preparedness technical

"a 10-year strategic partnership ... to strengthen the UK's mRNA capabilities and pandemic preparedness."

Pandemic preparedness is the planning, resources and systems organizations and governments put in place to prevent, detect and respond to widespread infectious disease outbreaks, like an emergency kit and playbook for public health. It matters to investors because strong preparedness can limit business disruptions, protect supply chains and reduce unexpected costs, while gaps can lead to sudden revenue losses, regulatory actions or costly pivots that affect a company’s value.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Lynch syndrome is an inherited condition affecting 1 in 300 people that causes lifetime cancer risk of up to 80%^[1]

The INTERCEPT-Lynch trial is part of a scientific collaboration between the University of Oxford and Moderna to advance a novel mRNA approach to cancer prevention

OXFORD, UK AND CAMBRIDGE, MA / ACCESS Newswire / June 8, 2026 / The University of Oxford and Moderna, Inc. (NASDAQ:MRNA) today announced a Phase 1/2 study of mRNA-4194, Moderna's investigational mRNA-based cancer vaccine for Lynch Syndrome, has received Medicines and Healthcare products Regulatory Agency (MHRA) authorization in the UK.

Lynch syndrome is an inherited condition that increases cancer risk. It is caused by alterations in genes responsible for repairing DNA, leading cells to accumulate DNA errors which can lead to cancer^[2]. It is the most common hereditary cancer predisposition condition, affecting 1 in 300 people^[3], and increases the risk of several cancer types, including colorectal, endometrial, ovarian, stomach, and prostate cancers^[4]. Today, care options for people with Lynch syndrome remain limited to regular surveillance, with low-dose aspirin and surgery used in select cases^[5].

mRNA-4194 is designed to generate immune responses against selected targets associated with early cancer development in people with Lynch syndrome. mRNA-4194 represents Moderna's first investigational cancer prevention program.

"This MHRA authorization marks an important milestone as we explore approaches to shift cancer care from treating disease to preventing it. By applying mRNA technology earlier in the patient journey, we aim to harness the immune system when it can have the greatest impact," said David Berman, M.D., Ph.D., Chief Development Officer, Moderna. "We are proud to bring this innovation to the UK, building on our long-standing collaboration with leading UK institutions to advance mRNA research and development. We are deeply grateful to the participants, investigators and partners who make this research possible."

The Phase 1/2 study, funded by Moderna, sponsored by the University of Oxford, and run by the University's Oncology Clinical Trials Office and Oxford Cancer Center, will administer mRNA-4194 to participants with Lynch syndrome to assess safety, characterize immune response and determine the optimal dose for further testing. Moderna and the University of Oxford anticipate the first patient to be dosed this summer. The second phase will expand enrollment across multiple centers in the UK, including Oxford, and is expected to begin in 2027.

"People with Lynch syndrome live with a very high risk of developing cancer, often at a younger age than the general population. The INTERCEPT-Lynch trial represents a meaningful step in our efforts to prevent Lynch syndrome-associated cancers before they develop," said Professor David Church, Cancer Research UK Senior Cancer Research Fellow in the University of Oxford's Centre for Human Genetics in the Nuffield Department of Medicine and the lead investigator in the trial. "By using mRNA vaccine technology to train the immune system to recognize early cancer changes, or what we call 'pre-cancer,' we hope to reduce cancer risk and ultimately improve the lives of people with this inherited condition."

This clinical trial is part of a 10-year strategic partnership between Moderna and the UK Government, established in 2022, to strengthen the UK's mRNA capabilities and pandemic preparedness. In addition to the construction of the Moderna Innovation and Technology Centre (MITC) in Harwell, Oxfordshire, which opened in September 2025, the collaboration includes significant investment in UK-based R&D, with more than 20 clinical trials delivered across 135 centers, involving more than 14,500 participants to date. The Moderna Strategic Partnership (MSP) is managed by the UK Health Security Agency (UKHSA) on behalf of the Department of Health and Social Care.

About precision prevention research at the University of Oxford

Precision prevention research focuses on groups of people at higher risk of developing cancer and matches them to biologically-targeted agents that aim to stop cancer from developing. The approach aims to delay or prevent cancer, improving outcomes while reducing the burden of complex treatments on individuals and healthcare systems. INTERCEPT-Lynch forms part of Oxford's expanding cancer precision prevention research programme.

About the University of Oxford

Oxford University has been placed number 1 in the Times Higher Education World University Rankings for the ninth year running, and number 3 in the QS World Rankings 2024. At the heart of this success are the twin-pillars of our ground-breaking research and innovation and our distinctive educational offer.

Oxford is world-famous for research and teaching excellence and home to some of the most talented people from across the globe. Our work helps the lives of millions, solving real-world problems through a huge network of partnerships and collaborations. The breadth and interdisciplinary nature of our research alongside our personalised approach to teaching sparks imaginative and inventive insights and solutions.

Through its research commercialisation arm, Oxford University Innovation, Oxford is the highest university patent filer in the UK and is ranked first in the UK for university spinouts, having created more than 300 new companies since 1988. Over a third of these companies have been created in the past five years. The university is a catalyst for prosperity in Oxfordshire and the United Kingdom, contributing £15.7 billion to the UK economy in 2018/19, and supports more than 28,000 full time jobs.

About Moderna

Moderna is a pioneer and leader in the field of mRNA medicine. Through the advancement of its technology platform, Moderna is reimagining how medicines are made to transform how we treat and prevent diseases. Since its founding, Moderna's mRNA platform has enabled the development of vaccines and therapeutics across infectious diseases, cancer, rare diseases and more.

With a global team and a unique culture, driven by the company's values and mindsets, Moderna's mission is to deliver the greatest possible impact to people through mRNA medicines. For more information about Moderna, please visit modernatx.com and connect with us on X, Facebook, Instagram, YouTube and LinkedIn.

Moderna Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including statements regarding: the potential of mRNA to target pre-cancerous cells before cancer develops; expectations regarding timing of the Phase 1 study, including commencement of the second phase in 2027; and Moderna's ongoing strategic partnership with the UK Government. In some cases, forward-looking statements can be identified by terminology such as "will," "may," "should," "could," "expects," "intends," "plans," "aims," "anticipates," "believes," "estimates," "predicts," "potential," "continue," or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. The forward-looking statements in this press release are neither promises nor guarantees, and you should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties, and other factors, many of which are beyond Moderna's control and which could cause actual results to differ materially from those expressed or implied by these forward-looking statements. These risks, uncertainties, and other factors include, among others, those risks and uncertainties described under the heading "Risk Factors" in Moderna's Annual Report on Form 10-K for the fiscal year ended December 31, 2025, filed with the U.S. Securities and Exchange Commission (SEC), and in subsequent filings made by Moderna with the SEC, which are available on the SEC's website at www.sec.gov. Except as required by law, Moderna disclaims any intention or responsibility for updating or revising any forward-looking statements contained in this press release in the event of new information, future developments or otherwise. These forward-looking statements are based on Moderna's current expectations and speak only as of the date of this press release.

University of Oxford Contacts

For interviews with Professor David Church, lead of the INTERCEPT-Lynch study, please contact the University of Oxford News Office: news.office@admin.ox.ac.uk.

Moderna Contacts

Media:

Chris Ridley
Vice President, Global Head of Communications
+1 617-800-3651
Chris.Ridley@modernatx.com

Investors:

Lavina Talukdar
Senior Vice President & Head of Investor Relations
+1 617-209-5834
Lavina.Talukdar@modernatx.com

[1] Sherman, S., Ojha, S. K., Menon, G., et al. (2025, January 19). Hereditary nonpolyposis colon cancer (Lynch syndrome). In StatPearls. StatPearls Publishing. https://www.ncbi.nlm.nih.gov/books/NBK564511/
[2] Mayo Clinic. (2025, December 2). Lynch syndrome: Symptoms and causes. https://www.mayoclinic.org/diseases-conditions/lynch-syndrome/symptoms-causes/syc-20374714
[3] Underkofler, K. A., & Ring, K. L. (2023). Updates in gynecologic care for individuals with Lynch syndrome. Frontiers in Oncology, 13, 1127683. https://doi.org/10.3389/fonc.2023.1127683
[4] American Cancer Society. (2024, May 13). Lynch syndrome. https://www.cancer.org/cancer/risk-prevention/genetics/family-cancer-syndromes/lynch-syndrome.html
[5] MD Anderson. (2024, April 24). Lynch syndrome: 10 things to know about this genetic condition. https://www.mdanderson.org/cancerwise/qa-understanding-and-managing-lynch-syndrome.h00-158589789.html

SOURCE: Moderna, Inc.

View the original press release on ACCESS Newswire

FAQ

What did Moderna (MRNA) announce about the mRNA-4194 Lynch syndrome vaccine on June 8, 2026?

Moderna announced UK MHRA authorization for a Phase 1/2 study of mRNA-4194 in people with Lynch syndrome. According to Moderna, the INTERCEPT-Lynch trial will evaluate safety, immune response and optimal dose as part of its first cancer prevention program.

What is the purpose of the INTERCEPT-Lynch Phase 1/2 trial for Moderna (MRNA)?

The INTERCEPT-Lynch trial aims to test mRNA-4194 as a preventive cancer vaccine for people with Lynch syndrome. According to Moderna, the study will assess safety, characterize immune responses and identify the optimal dose before broader testing at multiple UK centers.

When will participants first receive Moderna’s (MRNA) mRNA-4194 cancer vaccine in the UK?

Participants are expected to receive the first dose of mRNA-4194 in the UK in summer 2026. According to Moderna, this initial Phase 1/2 dosing precedes a second phase of expanded enrollment planned across several UK sites starting in 2027.

How does the mRNA-4194 Lynch syndrome trial fit into Moderna’s (MRNA) UK partnership?

The mRNA-4194 trial is part of a 10-year strategic partnership between Moderna and the UK government. According to Moderna, this collaboration includes the Harwell-based MITC facility and more than 20 UK clinical trials involving over 14,500 participants to date.

What is Lynch syndrome and why is Moderna (MRNA) targeting it with mRNA-4194?

Lynch syndrome is a hereditary condition affecting about 1 in 300 people and greatly increasing cancer risk. According to Moderna, mRNA-4194 is designed to trigger immune responses against early cancer-associated targets to help prevent Lynch syndrome-related cancers before they develop.